---
title: "Remibrutinib lowers relapse rates vs Aubagio in Phase 3 relapsing MS trials"
id: "stat-news-0-stat-novartis-multiple-sclerosis-treatment-cuts-rates-of-relapse-in-pivotal"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-novartis-multiple-sclerosis-treatment-cuts-rates-of-relapse-in-pivotal"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/?utm_campaign=rss"
published_at: "2026-10-23T16:47:31.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Remibrutinib lowers relapse rates vs Aubagio in Phase 3 relapsing MS trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-novartis-multiple-sclerosis-treatment-cuts-rates-of-relapse-in-pivotal
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/?utm_campaign=rss)
- **Published At:** 2026-10-23T16:47:31.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported two Phase 3 trials, REMODEL-1 and REMODEL-2, testing Novartis’ **remibrutinib** in **relapsing multiple sclerosis**. - The drug reduced the **annualized relapse rate** by 35.2% in one study and 31.2% in the other, versus Sanofi’s approved oral therapy **Aubagio**. - Heinz Wiendl, presenting the data in Toronto, calculated that the observed reductions translate roughly to one relapse every 13 years under the trial conditions. - The study team described remibrutinib’s safety profile as more favorable than competitors in aggregate; the source noted a “cleaner safety profile” but did not list specific adverse event rates or laboratory signals. - The article contrasted these results with Roche’s **fenebrutinib**, whose pivotal studies showed more than a 50% relapse-rate reduction versus Aubagio. - The source did not report dosing, sample sizes, statistical significance measures (p-values), detailed safety data, or regulatory plans. - Data were presented at an MS conference in Toronto; the published STAT piece summarized the topline efficacy comparisons and safety characterization reported by presenters.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [rare diseases](https://www.statnews.com/topic/rare-diseases/) [ESMO](https://www.statnews.com/topic/esmo/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials ## Treatment falls short of Roche’s experimental drug, but has favorable safety profile * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/?utm_campaign=rss) ![Multiple sclerosis brain](https://www.statnews.com/wp-content/uploads/2017/11/30805878966_8c941bf211_o-645x645.jpg) NIH ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Oct. 23, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have compared to a standard treatment, data presented Friday show. While that efficacy doesn’t match the performance of a rival drug from Roche, Novartis’ treatment has a cleaner safety profile that could give it a shot at being competitive in the market. In two Phase 3 studies in the relapsing form of MS, the Novartis drug, called remibrutinib, reduced the so-called annualized relapse rate by 35.2% and 31.2% when tested against Sanofi’s approved drug Aubagio. That translates into about one relapse every 13 years, Heinz Wiendl, a neurologist at the University of Freiburg, said while presenting the data from the REMODEL-1 and -2 studies at an MS conference in Toronto. Advertisement In its own pivotal studies, Roche’s drug fenebrutinib [cut the relapse rate](https://www.statnews.com/2026/04/21/roche-multiple-scleroris-efficacy-safety/) by more than 50% versus Aubagio. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [chronic disease](https://www.statnews.com/topic/chronic-disease/), [ESMO](https://www.statnews.com/topic/esmo/), [Novartis](https://www.statnews.com/topic/novartis/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/Andrea-Carol-Miranda-in-Medford-1990-80x80.jpg) [The inherited disease my family called ‘it’ had a name, which changed everything](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/https___cdn.sanity.io_images_xq1bjtf4_production_964fa47326a827f12bf336e880b2fdc4665711e6-5973x4480-1-80x80.jpg) [I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2299832720-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [State officials scrambling to implement Medicaid work requirements meet up to swap notes](https://www.statnews.com/2026/10/23/state-medicaid-officials-prepare-for-new-work-requirements/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2208174977-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In DOGE’s aftermath, federal health workers bristle at new performance reviews](https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/07/GLP1-48-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/4LK3WINEDMMIR2JEHVX56ICPOY-80x80.avif) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Jury rules in favor of ousted Cambridge scientist David Sabatini, with $6 million in damages to be awarded](https://www.statnews.com/2026/10/16/david-sabatini-wins-sexual-misconduct-lawsuit-metoo/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Tango builds on Revolution Medicines’ pancreatic cancer success ](https://www.statnews.com/2026/10/23/tango-pancreatic-cancer-star-moderna-readout-newsletter/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) and [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector ](https://www.statnews.com/2026/10/23/new-china-biotech-limits-coins-act-proposal-us-pharma-reaction/) By [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) and [Damian Garde](https://www.statnews.com/staff/damian-garde/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health tech Health tech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion ](https://www.statnews.com/2026/10/23/pathos-ai-bristol-myers-squibb-tempus-deal/) By [Katherine MacPhail](https://www.statnews.com/staff/katherine-macphail/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer ](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam says Huntington’s drug shows promise in early study ](https://www.statnews.com/2026/10/23/huntingtons-alnylam-gene-silencing-brezosiran/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) and [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: How the No Surprises Act’s nonprofit arbitrators are operating like 'mini gods' and getting rich doing it ](https://www.statnews.com/2026/10/19/no-surprises-act-billing-arbitration-profits-stat-investigation/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugmaking? ](https://www.statnews.com/2026/10
## Related Clinical Research

- [Patient death reported in Bristol Myers Squibb CAR-T trial for multiple sclerosis](https://medichelpline.com/clinical-feed/stat-news-2-stat-patient-dies-in-bristol-myers-squibb-autoimmune-car-t-trial.md)
- [Why a 13‑Year Diagnostic Delay in MS Resonates with Christina Applegate’s Case](https://medichelpline.com/clinical-feed/stat-news-1-opinion-it-took-me-13-years-to-be-diagnosed-with-ms-christina-applegate-s.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.